JFG
AXSM icon

Jefferies Financial Group’s Axsome Therapeutics AXSM Stock Holding History

Jefferies Financial Group’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-27,500
Closed -$2.33M – 1619
2024
Q4 		$2.33M Buy
+27,500
New +$2.53M 0.01% 622

Other funds holding AXSM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Jefferies Financial Group's AXSM Position: Q2 2026 in Review

Jefferies Financial Group increased its Axsome Therapeutics (AXSM) stake by 65% in Q2 2026, buying an estimated $2.2M and bringing the position to 25,628 shares worth $6.27M. The position accounts for 0.04% of the portfolio, ranked #339.

Jefferies Financial Group first reported a position in AXSM in Q3 2023 and has held it in 8 quarters since. The position peaked at $44.8M in Q4 2023. 505 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

  • Jefferies Financial Group held 25,628 shares of Axsome Therapeutics worth $6.27M as of Q2 2026.
  • Jefferies Financial Group bought 10,128 Axsome Therapeutics shares in Q2 2026, an estimated $2.2M.
  • Axsome Therapeutics made up 0.04% of Jefferies Financial Group's portfolio in Q2 2026, its #339 holding.
  • Jefferies Financial Group first reported a position in Axsome Therapeutics in Q3 2023 and has held it in 8 quarters since.
  • Jefferies Financial Group's Axsome Therapeutics position peaked at $44.8M in Q4 2023.
  • 505 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Jefferies Financial Group's 13F filing for Q2 2026, filed 17 Aug 2026.